{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:31:10Z","timestamp":1794360670076,"version":"4.9.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072160"],"award-info":[{"award-number":["82072160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32130060"],"award-info":[{"award-number":["32130060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901933"],"award-info":[{"award-number":["81901933"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000725"],"award-info":[{"award-number":["32000725"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Natural Science Research Projects in Universities of Jiangsu Province","award":["20KJA310012"],"award-info":[{"award-number":["20KJA310012"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20202013"],"award-info":[{"award-number":["BK20202013"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20201209"],"award-info":[{"award-number":["BK20201209"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20200973"],"award-info":[{"award-number":["BK20200973"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["JC22022037"],"award-info":[{"award-number":["JC22022037"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["MS22022010"],"award-info":[{"award-number":["MS22022010"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00415-023-11796-x","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T03:38:31Z","timestamp":1685590711000},"page":"3733-3749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Duchenne muscular dystrophy: pathogenesis and promising therapies"],"prefix":"10.1007","volume":"270","author":[{"given":"Mengyuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"issue":"1","key":"11796_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/antiox12010044","volume":"12","author":"L Huang","year":"2022","unstructured":"Huang L, Li M, Deng C, Qiu J, Wang K, Chang M, Zhou S, Gu Y, Shen Y, Wang W et al (2022) Potential therapeutic strategies for skeletal muscle atrophy. Antioxidants (Basel) 12(1):44","journal-title":"Antioxidants (Basel)"},{"key":"11796_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.114954","volume":"198","author":"W Wang","year":"2022","unstructured":"Wang W, Li M, Chen Z, Xu L, Chang M, Wang K, Deng C, Gu Y, Zhou S, Shen Y et al (2022) Biogenesis and function of extracellular vesicles in pathophysiological processes of skeletal muscle atrophy. Biochem Pharmacol 198:114954","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"11796_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1073\/pnas.1013067108","volume":"108","author":"AR Amenta","year":"2011","unstructured":"Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS, Fallon JR (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108(2):762\u2013767","journal-title":"Proc Natl Acad Sci USA"},{"key":"11796_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM (2015) The pathogenesis and therapy of muscular dystrophies. Annu Rev Genom Hum Genet 16:281\u2013308","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"1","key":"11796_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7(1):13","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"11796_CR6","doi-asserted-by":"publisher","first-page":"11040","DOI":"10.3390\/ijms222011040","volume":"22","author":"B Zablocka","year":"2021","unstructured":"Zablocka B, Gorecki DC, Zablocki K (2021) Disrupted calcium homeostasis in duchenne muscular dystrophy: a common mechanism behind diverse consequences. Int J Mol Sci 22(20):11040","journal-title":"Int J Mol Sci"},{"issue":"3","key":"11796_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM (2015) The dystrophin complex: structure, function, and implications for therapy. Compr Physiol 5(3):1223\u20131239","journal-title":"Compr Physiol"},{"issue":"3","key":"11796_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI36612","volume":"119","author":"Y Lai","year":"2009","unstructured":"Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL et al (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Investig 119(3):624\u2013635","journal-title":"J Clin Investig"},{"issue":"1","key":"11796_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC (2016) Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev 96(1):253\u2013305","journal-title":"Physiol Rev"},{"issue":"1","key":"11796_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13395-018-0182-x","volume":"8","author":"A Patel","year":"2018","unstructured":"Patel A, Zhao J, Yue Y, Zhang K, Duan D, Lai Y (2018) Dystrophin R16\/17-syntrophin PDZ fusion protein restores sarcolemmal nNOS\u03bc. Skelet Muscle 8(1):36","journal-title":"Skelet Muscle"},{"issue":"5","key":"11796_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","volume":"82","author":"JE Brenman","year":"1995","unstructured":"Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS (1995) Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82(5):743\u2013752","journal-title":"Cell"},{"issue":"25","key":"11796_CR12","doi-asserted-by":"publisher","first-page":"13818","DOI":"10.1073\/pnas.250379497","volume":"97","author":"M Sander","year":"2000","unstructured":"Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG (2000) Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 97(25):13818\u201313823","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"11796_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/hum.2017.095","volume":"29","author":"K Kodippili","year":"2018","unstructured":"Kodippili K, Hakim CH, Pan X, Yang HT, Yue Y, Zhang Y, Shin JH, Yang NN, Duan D (2018) Dual AAV gene therapy for duchenne muscular dystrophy with a 7-kb Mini-Dystrophin Gene in the canine model. Hum Gene Ther 29(3):299\u2013311","journal-title":"Hum Gene Ther"},{"issue":"6048","key":"11796_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.1202768","volume":"333","author":"BL Prosser","year":"2011","unstructured":"Prosser BL, Ward CW, Lederer WJ (2011) X-ROS signaling: rapid mechano-chemo transduction in heart. Science (New York, NY) 333(6048):1440\u20131445","journal-title":"Science (New York, NY)"},{"issue":"236","key":"11796_CR15","doi-asserted-by":"publisher","first-page":"ra56","DOI":"10.1126\/scisignal.2002829","volume":"5","author":"RJ Khairallah","year":"2012","unstructured":"Khairallah RJ, Shi G, Sbrana F, Prosser BL, Borroto C, Mazaitis MJ, Hoffman EP, Mahurkar A, Sachs F, Sun Y et al (2012) Microtubules underlie dysfunction in duchenne muscular dystrophy. Sci Signal 5(236):ra56","journal-title":"Sci Signal"},{"key":"11796_CR16","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1038\/ncomms5425","volume":"5","author":"R Pal","year":"2014","unstructured":"Pal R, Palmieri M, Loehr JA, Li S, Abo-Zahrah R, Monroe TO, Thakur PB, Sardiello M, Rodney GG (2014) Src-dependent impairment of autophagy by oxidative stress in a mouse model of Duchenne muscular dystrophy. Nat Commun 5:4425","journal-title":"Nat Commun"},{"key":"11796_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1196\/annals.1363.013","volume":"1066","author":"H Gissel","year":"2005","unstructured":"Gissel H (2005) The role of Ca2+ in muscle cell damage. Ann N Y Acad Sci 1066:166\u2013180","journal-title":"Ann N Y Acad Sci"},{"issue":"36","key":"11796_CR18","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1073\/pnas.1513047112","volume":"112","author":"G Santulli","year":"2015","unstructured":"Santulli G, Xie W, Reiken SR, Marks AR (2015) Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci USA 112(36):11389\u201311394","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"11796_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1083\/jcb.200403102","volume":"166","author":"R Rudolf","year":"2004","unstructured":"Rudolf R, Mongillo M, Magalh\u00e3es PJ, Pozzan T (2004) In vivo monitoring of Ca(2+) uptake into mitochondria of mouse skeletal muscle during contraction. J Cell Biol 166(4):527\u2013536","journal-title":"J Cell Biol"},{"issue":"3","key":"11796_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1152\/physrev.00026.2013","volume":"94","author":"DB Zorov","year":"2014","unstructured":"Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94(3):909\u2013950","journal-title":"Physiol Rev"},{"key":"11796_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103032","volume":"61","author":"SY Ng","year":"2020","unstructured":"Ng SY, Ljubicic V (2020) Recent insights into neuromuscular junction biology in Duchenne muscular dystrophy: impacts, challenges, and opportunities. EBioMedicine 61:103032","journal-title":"EBioMedicine"},{"key":"11796_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev-physiol-022516-034255","volume":"80","author":"L Li","year":"2018","unstructured":"Li L, Xiong WC, Mei L (2018) Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol 80:159\u2013188","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"11796_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","volume":"64","author":"SJ Wood","year":"2001","unstructured":"Wood SJ, Slater CR (2001) Safety factor at the neuromuscular junction. Prog Neurobiol 64(4):393\u2013429","journal-title":"Prog Neurobiol"},{"issue":"5","key":"11796_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.apsb.2020.01.001","volume":"10","author":"I Suntar","year":"2020","unstructured":"Suntar I, Sureda A, Belwal T, Sanches Silva A, Vacca RA, Tewari D, Sobarzo-S\u00e1nchez E, Nabavi SF, Shirooie S, Dehpour AR et al (2020) Natural products, PGC-1 \u03b1, and Duchenne muscular dystrophy. Acta Pharm Sin B 10(5):734\u2013745","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"11796_CR25","doi-asserted-by":"publisher","first-page":"C908","DOI":"10.1152\/ajpcell.00196.2005","volume":"289","author":"LM Angus","year":"2005","unstructured":"Angus LM, Chakkalakal JV, M\u00e9jat A, Eibl JK, B\u00e9langer G, Megeney LA, Chin ER, Schaeffer L, Michel RN, Jasmin BJ (2005) Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. Am J Physiol Cell Physiol 289(4):C908-917","journal-title":"Am J Physiol Cell Physiol"},{"issue":"37","key":"11796_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8787","volume":"7","author":"A Paredes-Redondo","year":"2021","unstructured":"Paredes-Redondo A, Harley P, Maniati E, Ryan D, Louzada S, Meng J, Kowala A, Fu B, Yang F, Liu P et al (2021) Optogenetic modeling of human neuromuscular circuits in Duchenne muscular dystrophy with CRISPR and pharmacological corrections. Sci Adv 7(37):eabi8787","journal-title":"Sci Adv"},{"issue":"1","key":"11796_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00018-014-1663-7","volume":"72","author":"SJP Pratt","year":"2015","unstructured":"Pratt SJP, Shah SB, Ward CW, Kerr JP, Stains JP, Lovering RM (2015) Recovery of altered neuromuscular junction morphology and muscle function in mdx mice after injury. Cell Mol Life Sci CMLS 72(1):153\u2013164","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"3","key":"11796_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.mcn.2005.10.020","volume":"31","author":"BA Hesser","year":"2006","unstructured":"Hesser BA, Henschel O, Witzemann V (2006) Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol Cell Neurosci 31(3):470\u2013480","journal-title":"Mol Cell Neurosci"},{"issue":"18","key":"11796_CR29","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1113\/JP277839","volume":"597","author":"S Trajanovska","year":"2019","unstructured":"Trajanovska S, Ban J, Huang J, Gregorevic P, Morsch M, Allen DG, Phillips WD (2019) Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity. J Physiol 597(18):4831\u20134850","journal-title":"J Physiol"},{"issue":"7","key":"11796_CR30","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/cells9071659","volume":"9","author":"O Cappellari","year":"2020","unstructured":"Cappellari O, Mantuano P, De Luca A (2020) \u201cThe social network\u201d and muscular dystrophies: the lesson learnt about the niche environment as a target for therapeutic strategies. Cells 9(7):1659","journal-title":"Cells"},{"issue":"5","key":"11796_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.stem.2018.03.022","volume":"22","author":"NC Chang","year":"2018","unstructured":"Chang NC, Sincennes MC, Chevalier FP, Brun CE, Lacaria M, Segal\u00e9s J, Mu\u00f1oz-C\u00e1noves P, Ming H, Rudnicki MA (2018) The dystrophin glycoprotein complex regulates the epigenetic activation of muscle stem cell commitment. Cell Stem Cell 22(5):755-768.e756","journal-title":"Cell Stem Cell"},{"issue":"7","key":"11796_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/10165","volume":"2","author":"C Lumeng","year":"1999","unstructured":"Lumeng C, Phelps S, Crawford GE, Walden PD, Barald K, Chamberlain JS (1999) Interactions between beta 2-syntrophin and a family of microtubule-associated serine\/threonine kinases. Nat Neurosci 2(7):611\u2013617","journal-title":"Nat Neurosci"},{"issue":"4","key":"11796_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/jdb3040129","volume":"3","author":"EB Dewey","year":"2015","unstructured":"Dewey EB, Taylor DT, Johnston CA (2015) Cell Fate decision making through oriented cell division. J Dev Biol 3(4):129\u2013157","journal-title":"J Dev Biol"},{"issue":"1","key":"11796_CR34","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbrc.2009.11.144","volume":"391","author":"K Yamashita","year":"2010","unstructured":"Yamashita K, Suzuki A, Satoh Y, Ide M, Amano Y, Masuda-Hirata M, Hayashi YK, Hamada K, Ogata K, Ohno S (2010) The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b. Biochem Biophys Res Commun 391(1):812\u2013817","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"11796_CR35","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont NA, Wang YX, von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, Rudnicki MA (2015) Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med 21(12):1455\u20131463","journal-title":"Nat Med"},{"issue":"267","key":"11796_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008411","volume":"6","author":"S Biressi","year":"2014","unstructured":"Biressi S, Miyabara EH, Gopinath SD, Carlig PM, Rando TA (2014) A Wnt-TGF\u03b22 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med 6(267):267ra176","journal-title":"Sci Transl Med"},{"issue":"4","key":"11796_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/cphy.c170052","volume":"8","author":"JG Tidball","year":"2018","unstructured":"Tidball JG, Welc SS, Wehling-Henricks M (2018) Immunobiology of inherited muscular dystrophies. Compr Physiol 8(4):1313\u20131356","journal-title":"Compr Physiol"},{"issue":"11","key":"11796_CR38","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1111\/febs.14417","volume":"285","author":"LA Perandini","year":"2018","unstructured":"Perandini LA, Chimin P, Lutkemeyer DDS, C\u00e2mara NOS (2018) Chronic inflammation in skeletal muscle impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche? FEBS J 285(11):1973\u20131984","journal-title":"FEBS J"},{"issue":"7","key":"11796_CR39","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.4049\/jimmunol.1103180","volume":"189","author":"B Deng","year":"2012","unstructured":"Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG (2012) IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J Immunology (Baltimore, Md: 1950) 189(7):3669\u20133680","journal-title":"J Immunology (Baltimore, Md: 1950)"},{"key":"11796_CR40","doi-asserted-by":"publisher","first-page":"5980465","DOI":"10.1155\/2019\/5980465","volume":"2019","author":"T Pavlidou","year":"2019","unstructured":"Pavlidou T, Marinkovic M, Rosina M, Fuoco C, Vumbaca S, Gargioli C, Castagnoli L, Cesareni G (2019) Metformin delays satellite cell activation and maintains quiescence. Stem Cells Int 2019:5980465","journal-title":"Stem Cells Int"},{"issue":"7","key":"11796_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm.3869","volume":"21","author":"DR Lemos","year":"2015","unstructured":"Lemos DR, Babaeijandaghi F, Low M, Chang CK, Lee ST, Fiore D, Zhang RH, Natarajan A, Nedospasov SA, Rossi FM (2015) Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro\/adipogenic progenitors. Nat Med 21(7):786\u2013794","journal-title":"Nat Med"},{"issue":"4","key":"11796_CR42","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/hmg\/ddq523","volume":"20","author":"SA Villalta","year":"2011","unstructured":"Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG (2011) Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet 20(4):790\u2013805","journal-title":"Hum Mol Genet"},{"issue":"3","key":"11796_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/hmg\/ddn376","volume":"18","author":"SA Villalta","year":"2009","unstructured":"Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG (2009) Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 18(3):482\u2013496","journal-title":"Hum Mol Genet"},{"issue":"9869","key":"11796_CR44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","volume":"381","author":"E Mercuri","year":"2013","unstructured":"Mercuri E, Muntoni F (2013) Muscular dystrophies. Lancet (London, England) 381(9869):845\u2013860","journal-title":"Lancet (London, England)"},{"key":"11796_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-7374-3_2","volume":"1687","author":"T Tsuda","year":"2018","unstructured":"Tsuda T (2018) Clinical manifestations and overall management strategies for Duchenne muscular dystrophy. Methods Mol Biol (Clifton, NJ) 1687:19\u201328","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"4","key":"11796_CR46","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.pmr.2005.08.017","volume":"16","author":"JO Benditt","year":"2005","unstructured":"Benditt JO, Boitano L (2005) Respiratory support of individuals with Duchenne muscular dystrophy: toward a standard of care. Phys Med Rehabil Clin N Am 16(4):1125\u20131139, xii","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"8","key":"11796_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043515","volume":"7","author":"EK Johnson","year":"2012","unstructured":"Johnson EK, Zhang L, Adams ME, Phillips A, Freitas MA, Froehner SC, Green-Church KB, Montanaro F (2012) Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins. PLoS ONE 7(8):e43515","journal-title":"PLoS ONE"},{"issue":"6","key":"11796_CR48","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","volume":"45","author":"D Duboc","year":"2005","unstructured":"Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, B\u00e9cane HM (2005) Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45(6):855\u2013857","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"11796_CR49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamacardio.2016.4801","volume":"2","author":"MC Silva","year":"2017","unstructured":"Silva MC, Magalh\u00e3es TA, Meira ZM, Rassi CH, Andrade AC, Gutierrez PS, Azevedo CF, Gurgel-Giannetti J, Vainzof M, Zatz M et al (2017) Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial. JAMA cardiology 2(2):190\u2013199","journal-title":"JAMA cardiology"},{"issue":"4","key":"11796_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.nmd.2013.01.011","volume":"23","author":"M Pane","year":"2013","unstructured":"Pane M, Messina S, Bruno C, D\u2019Amico A, Villanova M, Brancalion B, Sivo S, Bianco F, Striano P, Battaglia D et al (2013) Duchenne muscular dystrophy and epilepsy. Neuromusc Disord NMD 23(4):313\u2013315","journal-title":"Neuromusc Disord NMD"},{"issue":"Suppl 1","key":"11796_CR51","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1038\/sj.gt.3302379","volume":"11","author":"T Athanasopoulos","year":"2004","unstructured":"Athanasopoulos T, Graham IR, Foster H, Dickson G (2004) Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11(Suppl 1):S109-121","journal-title":"Gene Ther"},{"issue":"677","key":"11796_CR52","doi-asserted-by":"publisher","first-page":"eabo1815","DOI":"10.1126\/scitranslmed.abo1815","volume":"15","author":"SM Birch","year":"2023","unstructured":"Birch SM, Lawlor MW, Conlon TJ, Guo LJ, Crudele JM, Hawkins EC, Nghiem PP, Ahn M, Meng H, Beatka MJ et al (2023) Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med 15(677):eabo1815","journal-title":"Sci Transl Med"},{"issue":"9","key":"11796_CR53","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, Iammarino MA, Alfano LN, Nicholl A, Al-Zaidy S et al (2020) Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol 77(9):1122\u20131131","journal-title":"JAMA Neurol"},{"issue":"2","key":"11796_CR54","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","volume":"20","author":"DE Bowles","year":"2012","unstructured":"Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE et al (2012) Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20(2):443\u2013455","journal-title":"Mol Ther"},{"issue":"7","key":"11796_CR55","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","volume":"29","author":"D Duan","year":"2018","unstructured":"Duan D (2018) Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Hum Gene Ther 29(7):733\u2013736","journal-title":"Hum Gene Ther"},{"key":"11796_CR56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","volume":"70","author":"YL Min","year":"2019","unstructured":"Min YL, Bassel-Duby R, Olson EN (2019) CRISPR correction of Duchenne muscular dystrophy. Annu Rev Med 70:239\u2013255","journal-title":"Annu Rev Med"},{"issue":"22","key":"11796_CR57","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1161\/CIRCULATIONAHA.121.054628","volume":"144","author":"J Li","year":"2021","unstructured":"Li J, Wang K, Zhang Y, Qi T, Yuan J, Zhang L, Qiu H, Wang J, Yang HT, Dai Y et al (2021) Therapeutic exon skipping through a CRISPR-guided cytidine deaminase rescues dystrophic cardiomyopathy in vivo. Circulation 144(22):1760\u20131776","journal-title":"Circulation"},{"issue":"2","key":"11796_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","volume":"26","author":"A Moretti","year":"2020","unstructured":"Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier AB, Bozoglu T, Baehr A, Schneider CM, Sinnecker D, Klett K et al (2020) Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med 26(2):207\u2013214","journal-title":"Nat Med"},{"key":"11796_CR59","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.omtn.2021.03.005","volume":"24","author":"X Xiang","year":"2021","unstructured":"Xiang X, Zhao X, Pan X, Dong Z, Yu J, Li S, Liang X, Han P, Qu K, Jensen JB et al (2021) Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs. Mol Ther Nucleic Acids 24:403\u2013415","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"11796_CR60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/mt.2015.192","volume":"24","author":"L Xu","year":"2016","unstructured":"Xu L, Park KH, Zhao L, Xu J, El Refaey M, Gao Y, Zhu H, Ma J, Han R (2016) CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther 24(3):564\u2013569","journal-title":"Mol Ther"},{"issue":"1","key":"11796_CR61","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo E, Hozumi H, Makita Y, Iwabuchi KA, Fujimoto N, Matsumoto S, Kimura M, Amano Y, Ifuku M, Naoe Y et al (2021) Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun 12(1):7101","journal-title":"Nat Commun"},{"issue":"8","key":"11796_CR62","doi-asserted-by":"publisher","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","volume":"6","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li H, Min YL, Sanchez-Ortiz E, Huang J, Mireault AA, Shelton JM, Kim J, Mammen PPA, Bassel-Duby R et al (2020) Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system. Sci Adv 6(8):eaay6812","journal-title":"Sci Adv"},{"issue":"7","key":"11796_CR63","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.ymthe.2022.05.023","volume":"30","author":"N Majeau","year":"2022","unstructured":"Majeau N, Fortin-Archambault A, G\u00e9rard C, Rousseau J, Yam\u00e9ogo P, Tremblay JP (2022) Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene. Mol Ther 30(7):2429\u20132442","journal-title":"Mol Ther"},{"issue":"11","key":"11796_CR64","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","volume":"29","author":"A Pickar-Oliver","year":"2021","unstructured":"Pickar-Oliver A, Gough V, Bohning JD, Liu S, Robinson-Hamm JN, Daniels H, Majoros WH, Devlin G, Asokan A, Gersbach CA (2021) Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther 29(11):3243\u20133257","journal-title":"Mol Ther"},{"issue":"5","key":"11796_CR65","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/hum.2012.234","volume":"24","author":"T Koo","year":"2013","unstructured":"Koo T, Wood MJ (2013) Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum Gene Ther 24(5):479\u2013488","journal-title":"Hum Gene Ther"},{"issue":"2","key":"11796_CR66","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012993","volume":"13","author":"N Ran","year":"2021","unstructured":"Ran N, Lin C, Leng L, Han G, Geng M, Wu Y, Bittner S, Moulton HM, Yin H (2021) MOTS-c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice. EMBO Mol Med 13(2):e12993","journal-title":"EMBO Mol Med"},{"issue":"5","key":"11796_CR67","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.ymthe.2020.03.003","volume":"28","author":"C Lin","year":"2020","unstructured":"Lin C, Han G, Ning H, Song J, Ran N, Yi X, Seow Y, Yin H (2020) Glycine enhances satellite cell proliferation, cell transplantation, and oligonucleotide efficacy in dystrophic muscle. Mol Ther 28(5):1339\u20131358","journal-title":"Mol Ther"},{"issue":"9","key":"11796_CR68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112546119","volume":"119","author":"KRQ Lim","year":"2022","unstructured":"Lim KRQ, Woo S, Melo D, Huang Y, Dzierlega K, Shah MNA, Aslesh T, Roshmi RR, Echigoya Y, Maruyama R et al (2022) Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 119(9):e2112546119","journal-title":"Proc Natl Acad Sci USA"},{"key":"11796_CR69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.omtn.2022.10.025","volume":"30","author":"LV Gushchina","year":"2022","unstructured":"Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G et al (2022) Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids 30:479\u2013492","journal-title":"Mol Ther Nucleic Acids"},{"issue":"20","key":"11796_CR70","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","volume":"50","author":"CA Desjardins","year":"2022","unstructured":"Desjardins CA, Yao M, Hall J, O\u2019Donnell E, Venkatesan R, Spring S, Wen A, Hsia N, Shen P, Russo R et al (2022) Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res 50(20):11401\u201311414","journal-title":"Nucleic Acids Res"},{"key":"11796_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","volume":"30","author":"L Gan","year":"2022","unstructured":"Gan L, Wu LCL, Wood JA, Yao M, Treleaven CM, Estrella NL, Wentworth BM, Hanson GJ, Passini MA (2022) A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice. Mol Ther Nucleic Acids 30:17\u201327","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"11796_CR72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-020-01106-1","volume":"9","author":"D Scaglioni","year":"2021","unstructured":"Scaglioni D, Catapano F, Ellis M, Torelli S, Chambers D, Feng L, Beck M, Sewry C, Monforte M, Harriman S et al (2021) The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy. Acta Neuropathol Commun 9(1):7","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"11796_CR73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JND-210643","volume":"8","author":"CM McDonald","year":"2021","unstructured":"McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, Goemans N, Mercuri E, Khan N, Koenig E et al (2021) Open-label evaluation of eteplirsen in patients with duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI Trial. J Neuromusc Dis 8(6):989\u20131001","journal-title":"J Neuromusc Dis"},{"issue":"1","key":"11796_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-210665","volume":"9","author":"O Mitelman","year":"2022","unstructured":"Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S et al (2022) A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment. J Neuromusc Dis 9(1):39\u201352","journal-title":"J Neuromusc Dis"},{"issue":"3","key":"11796_CR75","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mus.27662","volume":"66","author":"J Iff","year":"2022","unstructured":"Iff J, Gerrits C, Zhong Y, Tuttle E, Birk E, Zheng Y, Paul X, Henricson EK, McDonald CM (2022) Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy. Muscle Nerve 66(3):262\u2013269","journal-title":"Muscle Nerve"},{"issue":"3","key":"11796_CR76","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB (2021) Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 64(3):285\u2013292","journal-title":"Muscle Nerve"},{"key":"11796_CR77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-0716-2772-3_2","volume":"2587","author":"RR Roshmi","year":"2023","unstructured":"Roshmi RR, Yokota T (2023) Viltolarsen: from preclinical studies to FDA approval. Methods Mol Biol (Clifton, NJ) 2587:31\u201341","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"4","key":"11796_CR78","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JND-220811","volume":"9","author":"PR Clemens","year":"2022","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, McDonald CM, Smith EC, Zaidman CM, Nakagawa T, Hoffman EP (2022) Long-term functional efficacy and safety of viltolarsen in patients with Duchenne muscular dystrophy. J Neuromusc Dis 9(4):493\u2013501","journal-title":"J Neuromusc Dis"},{"issue":"8","key":"11796_CR79","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H et al (2020) Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol 77(8):982\u2013991","journal-title":"JAMA Neurol"},{"issue":"12","key":"11796_CR80","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Takeshita E, Iwata Y, Yajima H, Egawa Y, Toramoto T et al (2020) Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study. Ann Clin Transl Neurol 7(12):2393\u20132408","journal-title":"Ann Clin Transl Neurol"},{"issue":"5702","key":"11796_CR81","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1126\/science.1104297","volume":"306","author":"A Goyenvalle","year":"2004","unstructured":"Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science (New York, NY) 306(5702):1796\u20131799","journal-title":"Science (New York, NY)"},{"key":"11796_CR82","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.omtm.2020.03.011","volume":"17","author":"A Forand","year":"2020","unstructured":"Forand A, Muchir A, Mougenot N, Sevoz-Couche C, Peccate C, Lemaitre M, Izabelle C, Wood M, Lorain S, Pi\u00e9tri-Rouxel F (2020) Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer-PPMO and AAV-U7 rescues the severe DMD phenotype in mice. Mol Ther Methods Clin Dev 17:695\u2013708","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"11796_CR83","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans N, Haberlova J et al (2022) Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol 79(10):1005\u20131014","journal-title":"JAMA Neurol"},{"issue":"9","key":"11796_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM et al (2020) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med 17(9):e1003222","journal-title":"PLoS Med"},{"issue":"4","key":"11796_CR85","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1302\/1863-2548.14.200033","volume":"14","author":"C Wei\u00df","year":"2020","unstructured":"Wei\u00df C, Stoltenburg C, Bayram D, Funk J, Lebek S (2020) Positive effect of the combination of multilevel contracture release and glucocorticoid treatment in Duchenne muscular dystrophy. J Child Orthop 14(4):349\u2013352","journal-title":"J Child Orthop"},{"key":"11796_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104999","volume":"159","author":"SC Previtali","year":"2020","unstructured":"Previtali SC, Gidaro T, D\u00edaz-Manera J, Zambon A, Carnesecchi S, Roux-Lombard P, Spitali P, Signorelli M, Szigyarto CA, Johansson C et al (2020) Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase Ib trial in young patients with Duchenne muscular dystrophy. Pharmacol Res 159:104999","journal-title":"Pharmacol Res"},{"issue":"2","key":"11796_CR87","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/acn3.50978","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki H, Maegaki Y, Matsumura T, Shiraishi K, Awano H, Nakamura A, Kinoshita S, Ogata K, Ishigaki K, Saitoh S et al (2020) Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol 7(2):181\u2013190","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"11796_CR88","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JND-210689","volume":"8","author":"RS Finkel","year":"2021","unstructured":"Finkel RS, McDonald CM, Lee Sweeney H, Finanger E, Neil Knierbein E, Wagner KR, Mathews KD, Marks W, Statland J, Nance J et al (2021) A randomized, double-blind, placebo-controlled, global phase 3 study of edasalonexent in pediatric patients with Duchenne muscular dystrophy: results of the PolarisDMD trial. J Neuromusc Dis 8(5):769\u2013784","journal-title":"J Neuromusc Dis"},{"issue":"12","key":"11796_CR89","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00198-020-05549-z","volume":"31","author":"N Nasomyont","year":"2020","unstructured":"Nasomyont N, Keefe C, Tian C, Hornung L, Khoury J, Tilden JC, Hochwalt P, Jackson E, Rybalsky I, Wong BL et al (2020) Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporos Int 31(12):2449\u20132459","journal-title":"Osteoporos Int"},{"issue":"7","key":"11796_CR90","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nmd.2020.06.005","volume":"30","author":"C Tian","year":"2020","unstructured":"Tian C, Wong BL, Hornung L, Khoury JC, Rybalsky I, Shellenbarger KC, Rutter MM (2020) Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Neuromusc Disord NMD 30(7):599\u2013610","journal-title":"Neuromusc Disord NMD"},{"issue":"1","key":"11796_CR91","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1038\/s41467-020-19839-x","volume":"11","author":"M Segatto","year":"2020","unstructured":"Segatto M, Szokoll R, Fittipaldi R, Bottino C, Nevi L, Mamchaoui K, Filippakopoulos P, Caretti G (2020) BETs inhibition attenuates oxidative stress and preserves muscle integrity in Duchenne muscular dystrophy. Nat Commun 11(1):6108","journal-title":"Nat Commun"},{"issue":"3","key":"11796_CR92","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/03007995.2020.1865699","volume":"37","author":"E Rybalka","year":"2021","unstructured":"Rybalka E, Goodman CA, Campelj DG, Hayes A, Timpani CA (2021) Adenylosuccinic acid: a novel inducer of the cytoprotectant Nrf2 with efficacy in Duchenne muscular dystrophy. Curr Med Res Opin 37(3):465\u2013467","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"11796_CR93","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41598-020-57610-w","volume":"10","author":"CA Timpani","year":"2020","unstructured":"Timpani CA, Goodman CA, Stathis CG, White JD, Mamchaoui K, Butler-Browne G, Gueven N, Hayes A, Rybalka E (2020) Adenylosuccinic acid therapy ameliorates murine Duchenne muscular dystrophy. Sci Rep 10(1):1125","journal-title":"Sci Rep"},{"issue":"1","key":"11796_CR94","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1038\/s41467-021-26516-0","volume":"12","author":"J Dort","year":"2021","unstructured":"Dort J, Orfi Z, Fabre P, Molina T, Conte TC, Greffard K, Pellerito O, Bilodeau JF, Dumont NA (2021) Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy. Nat Commun 12(1):6264","journal-title":"Nat Commun"},{"issue":"15","key":"11796_CR95","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.3390\/ijms22158016","volume":"22","author":"SM Krishnan","year":"2021","unstructured":"Krishnan SM, Nordlohne J, Dietz L, Vakalopoulos A, Haning P, Hartmann E, Seifert R, Huser J, Mathar I, Sandner P (2021) Assessing the use of the sGC stimulator BAY-747, as a potential treatment for Duchenne muscular dystrophy. Int J Mol Sci 22(15):8016","journal-title":"Int J Mol Sci"},{"key":"11796_CR96","doi-asserted-by":"publisher","first-page":"1049076","DOI":"10.3389\/fimmu.2022.1049076","volume":"13","author":"N Dubuisson","year":"2022","unstructured":"Dubuisson N, Davis-L\u00f3pez de Carrizosa MA, Versele R, Selvais CM, Noel L, Van den Bergh PYD, Brichard SM, Abou-Samra M (2022) Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy. Front Immunol 13:1049076","journal-title":"Front Immunol"},{"issue":"2","key":"11796_CR97","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jcsm.12531","volume":"11","author":"M Abou-Samra","year":"2020","unstructured":"Abou-Samra M, Selvais CM, Boursereau R, Lecompte S, Noel L, Brichard SM (2020) AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle 11(2):518\u2013533","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"11796_CR98","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymthe.2019.08.016","volume":"28","author":"RM Hightower","year":"2020","unstructured":"Hightower RM, Reid AL, Gibbs DE, Wang Y, Widrick JJ, Kunkel LM, Kastenschmidt JM, Villalta SA, van Groen T, Chang H et al (2020) The SINE compound KPT-350 blocks dystrophic pathologies in DMD zebrafish and mice. Mol Ther 28(1):189\u2013201","journal-title":"Mol Ther"},{"issue":"10","key":"11796_CR99","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/biomedicines10102400","volume":"10","author":"KG English","year":"2022","unstructured":"English KG, Reid AL, Samani A, Coulis GJF, Villalta SA, Walker CJ, Tamir S, Alexander MS (2022) Next-generation SINE compound KPT-8602 ameliorates dystrophic pathology in zebrafish and mouse models of DMD. Biomedicines 10(10):2400","journal-title":"Biomedicines"},{"issue":"5","key":"11796_CR100","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/jcsm.12581","volume":"11","author":"D Xu","year":"2020","unstructured":"Xu D, Zhao L, Jiang J, Li S, Sun Z, Huang X, Li C, Wang T, Sun L, Li X et al (2020) A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1. J Cachexia Sarcopenia Muscle 11(5):1306\u20131320","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"11796_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105421","volume":"165","author":"A Stocco","year":"2021","unstructured":"Stocco A, Smolina N, Sabatelli P, \u0160ileikyt\u0117 J, Artusi E, Mouly V, Cohen M, Forte M, Schiavone M, Bernardi P (2021) Treatment with a triazole inhibitor of the mitochondrial permeability transition pore fully corrects the pathology of sapje zebrafish lacking dystrophin. Pharmacol Res 165:105421","journal-title":"Pharmacol Res"},{"issue":"3","key":"11796_CR102","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ymthe.2020.11.021","volume":"29","author":"MR Lambert","year":"2021","unstructured":"Lambert MR, Spinazzola JM, Widrick JJ, Pakula A, Conner JR, Chin JE, Owens JM, Kunkel LM (2021) PDE10A inhibition reduces the manifestation of pathology in DMD zebrafish and represses the genetic modifier PITPNA. Mol Ther 29(3):1086\u20131101","journal-title":"Mol Ther"},{"issue":"1","key":"11796_CR103","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13395-020-00251-4","volume":"10","author":"GH Farr 3rd","year":"2020","unstructured":"Farr GH 3rd, Morris M, Gomez A, Pham T, Kilroy E, Parker EU, Said S, Henry C, Maves L (2020) A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy. Skelet Muscle 10(1):29","journal-title":"Skelet Muscle"},{"key":"11796_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105750","volume":"170","author":"M Spreafico","year":"2021","unstructured":"Spreafico M, Cafora M, Bragato C, Capitanio D, Marasca F, Bodega B, De Palma C, Mora M, Gelfi C, Marozzi A et al (2021) Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy. Pharmacol Res 170:105750","journal-title":"Pharmacol Res"},{"issue":"1","key":"11796_CR105","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s42003-022-04212-z","volume":"5","author":"RA Ellwood","year":"2022","unstructured":"Ellwood RA, Slade L, Lewis J, Torregrossa R, Sudevan S, Piasecki M, Whiteman M, Etheridge T, Szewczyk NJ (2022) Sulfur amino acid supplementation displays therapeutic potential in a C. elegans model of Duchenne muscular dystrophy. Commun Biol 5(1):1255","journal-title":"Commun Biol"},{"issue":"9","key":"11796_CR106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018342118","volume":"118","author":"RA Ellwood","year":"2021","unstructured":"Ellwood RA, Hewitt JE, Torregrossa R, Philp AM, Hardee JP, Hughes S, van de Klashorst D, Gharahdaghi N, Anupom T, Slade L et al (2021) Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans Duchenne muscular dystrophy model. Proc Natl Acad Sci USA 118(9):e2018342118","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"11796_CR107","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/ijms23042256","volume":"23","author":"J Morroni","year":"2022","unstructured":"Morroni J, Schirone L, Valenti V, Zwergel C, Riera CS, Valente S, Vecchio D, Schiavon S, Ragno R, Mai A et al (2022) Inhibition of PKCtheta improves dystrophic heart phenotype and function in a novel model of DMD cardiomyopathy. Int J Mol Sci 23(4):2256","journal-title":"Int J Mol Sci"},{"issue":"10","key":"11796_CR108","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41418-022-00979-0","volume":"29","author":"Z Guo","year":"2022","unstructured":"Guo Z, Geng M, Huang Y, Han G, Jing R, Lin C, Zhang X, Zhang M, Fan G, Wang F et al (2022) Upregulation of Wilms\u2019 Tumor 1 in epicardial cells increases cardiac fibrosis in dystrophic mice. Cell Death Differ 29(10):1928\u20131940","journal-title":"Cell Death Differ"},{"key":"11796_CR109","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.actbio.2020.10.009","volume":"118","author":"D Huang","year":"2020","unstructured":"Huang D, Yue F, Qiu J, Deng M, Kuang S (2020) Polymeric nanoparticles functionalized with muscle-homing peptides for targeted delivery of phosphatase and tensin homolog inhibitor to skeletal muscle. Acta Biomater 118:196\u2013206","journal-title":"Acta Biomater"},{"issue":"1","key":"11796_CR110","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12967-021-03191-9","volume":"19","author":"A Creism\u00e9as","year":"2021","unstructured":"Creism\u00e9as A, Gazaille C, Bourdon A, Lallemand MA, Fran\u00e7ois V, Allais M, Ledevin M, Larcher T, Toumaniantz G, Lafoux A et al (2021) TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD. J Transl Med 19(1):519","journal-title":"J Transl Med"},{"issue":"3","key":"11796_CR111","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ymthe.2019.12.011","volume":"28","author":"NB Wasala","year":"2020","unstructured":"Wasala NB, Yue Y, Lostal W, Wasala LP, Niranjan N, Hajjar RJ, Babu GJ, Duan D (2020) Single SERCA2a therapy ameliorated dilated cardiomyopathy for 18 months in a mouse model of Duchenne muscular dystrophy. Mol Ther 28(3):845\u2013854","journal-title":"Mol Ther"},{"issue":"11","key":"11796_CR112","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/pharmaceutics14112336","volume":"14","author":"MV Dubinin","year":"2022","unstructured":"Dubinin MV, Starinets VS, Belosludtseva NV, Mikheeva IB, Chelyadnikova YA, Igoshkina AD, Vafina AB, Vedernikov AA, Belosludtsev KN (2022) BK(Ca) activator NS1619 improves the structure and function of skeletal muscle mitochondria in Duchenne dystrophy. Pharmaceutics 14(11):2336","journal-title":"Pharmaceutics"},{"issue":"10","key":"11796_CR113","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jacc.2019.12.066","volume":"75","author":"F Kamdar","year":"2020","unstructured":"Kamdar F, Das S, Gong W, Klaassen Kamdar A, Meyers TA, Shah P, Ervasti JM, Townsend D, Kamp TJ, Wu JC et al (2020) Stem cell-derived cardiomyocytes and beta-adrenergic receptor blockade in Duchenne muscular dystrophy cardiomyopathy. J Am Coll Cardiol 75(10):1159\u20131174","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"11796_CR114","doi-asserted-by":"publisher","first-page":"eaaz2736","DOI":"10.1126\/sciadv.aaz2736","volume":"6","author":"L Yu","year":"2020","unstructured":"Yu L, Zhang X, Yang Y, Li D, Tang K, Zhao Z, He W, Wang C, Sahoo N, Converso-Baran K et al (2020) Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models. Sci Adv 6(6):eaaz2736","journal-title":"Sci Adv"},{"issue":"588","key":"11796_CR115","doi-asserted-by":"publisher","first-page":"eabb0319","DOI":"10.1126\/scitranslmed.abb0319","volume":"13","author":"P Luan","year":"2021","unstructured":"Luan P, D\u2019Amico D, Andreux PA, Laurila PP, Wohlwend M, Li H, de Lima TI, Place N, Rinsch C, Zanou N et al (2021) Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy. Sci Transl Med 13(588):eabb0319","journal-title":"Sci Transl Med"},{"issue":"11","key":"11796_CR116","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41556-020-00595-5","volume":"22","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li Y, Hu Q, Xi Y, Xing Z, Zhang Z, Huang L, Wu J, Liang K, Nguyen TK et al (2020) The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol 22(11):1332\u20131345","journal-title":"Nat Cell Biol"},{"issue":"14","key":"11796_CR117","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1093\/hmg\/ddac042","volume":"31","author":"A Oliveira-Santos","year":"2022","unstructured":"Oliveira-Santos A, Dagda M, Burkin DJ (2022) Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy. Hum Mol Genet 31(14):2358\u20132369","journal-title":"Hum Mol Genet"},{"issue":"1","key":"11796_CR118","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/1061186X.2019.1613408","volume":"28","author":"D Haupenthal","year":"2020","unstructured":"Haupenthal D, Possato JC, Zaccaron RP, Mendes C, Rodrigues MS, Nesi RT, Pinho RA, Feuser PE, Machado-de-\u00c1vila RA, Comim CM et al (2020) Effects of chronic treatment with gold nanoparticles on inflammatory responses and oxidative stress in Mdx mice. J Drug Target 28(1):46\u201354","journal-title":"J Drug Target"},{"issue":"4","key":"11796_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138634","volume":"131","author":"J Li","year":"2021","unstructured":"Li J, Fredericks M, Cannell M, Wang K, Sako D, Maguire MC, Grenha R, Liharska K, Krishnan L, Bloom T et al (2021) ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Investig 131(4):e138634","journal-title":"J Clin Investig"},{"issue":"1","key":"11796_CR120","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911019","volume":"12","author":"P Bella","year":"2020","unstructured":"Bella P, Farini A, Banfi S, Parolini D, Tonna N, Meregalli M, Belicchi M, Erratico S, D\u2019Ursi P, Bianco F et al (2020) Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy. EMBO Mol Med 12(1):e11019","journal-title":"EMBO Mol Med"},{"issue":"16","key":"11796_CR121","doi-asserted-by":"publisher","first-page":"9059","DOI":"10.3390\/ijms23169059","volume":"23","author":"DK Sung","year":"2022","unstructured":"Sung DK, Kim H, Park SE, Lee J, Kim JA, Park YC, Jeon HB, Chang JW, Lee J (2022) A new method of myostatin inhibition in mice via oral administration of Lactobacillus casei expressing modified myostatin protein, BLS-M22. Int J Mol Sci 23(16):9059","journal-title":"Int J Mol Sci"},{"key":"11796_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119826","volume":"236","author":"N Ran","year":"2020","unstructured":"Ran N, Gao X, Dong X, Li J, Lin C, Geng M, Yin H (2020) Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice. Biomaterials 236:119826","journal-title":"Biomaterials"},{"issue":"1","key":"11796_CR123","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/jcsm.12650","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Li S, Wang L, Jiang J, Zhao L, Huang X, Sun Z, Li C, Sun L, Li X et al (2021) TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle 12(1):192\u2013208","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"11796_CR124","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/01.jnen.0000218443.45782.81","volume":"65","author":"D Skuk","year":"2006","unstructured":"Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, Dugr\u00e9 FJ, Sylvain M, Lachance JG, Desch\u00eanes L et al (2006) Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 65(4):371\u2013386","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"11796_CR125","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13287-020-02099-3","volume":"12","author":"Y Nitahara-Kasahara","year":"2021","unstructured":"Nitahara-Kasahara Y, Kuraoka M, Guillermo PH, Hayashita-Kinoh H, Maruoka Y, Nakamura-Takahasi A, Kimura K, Takeda S, Okada T (2021) Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy. Stem Cell Res Ther 12(1):78","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"11796_CR126","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s13770-022-00489-7","volume":"19","author":"S Park","year":"2022","unstructured":"Park S, Jeong S, Nam YH, Yum Y, Jung SC (2022) Transplantation of differentiated tonsil-derived mesenchymal stem cells ameliorates murine Duchenne muscular dystrophy via autophagy activation. Tissue Eng Regen Med 19(6):1283\u20131294","journal-title":"Tissue Eng Regen Med"},{"issue":"8","key":"11796_CR127","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1007\/s12015-022-10384-2","volume":"18","author":"M Siemionow","year":"2022","unstructured":"Siemionow M, Langa P, Brodowska S, Kozlowska K, Zalants K, Budzynska K, Heydemann A (2022) Long-term protective effect of human dystrophin expressing chimeric (DEC) cell therapy on amelioration of function of cardiac, respiratory and skeletal muscles in Duchenne muscular dystrophy. Stem Cell Rev Rep 18(8):2872\u20132892","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"11796_CR128","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/scd.2020.0161","volume":"30","author":"M Siemionow","year":"2021","unstructured":"Siemionow M, Szilagyi E, Cwykiel J, Domaszewska-Szostek A, Heydemann A, Garcia-Martinez J, Siemionow K (2021) Transplantation of dystrophin expressing chimeric human cells of myoblast\/mesenchymal stem cell origin improves function in Duchenne muscular dystrophy model. Stem Cells Dev 30(4):190\u2013202","journal-title":"Stem Cells Dev"},{"issue":"3\u20134","key":"11796_CR129","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/hum.2019.224","volume":"31","author":"J Meng","year":"2020","unstructured":"Meng J, Sweeney NP, Doreste B, Muntoni F, McClure M, Morgan J (2020) Restoration of functional full-length dystrophin after intramuscular transplantation of foamy virus-transduced myoblasts. Hum Gene Ther 31(3\u20134):241\u2013252","journal-title":"Hum Gene Ther"},{"issue":"8","key":"11796_CR130","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1096\/fj.04-1956rev","volume":"19","author":"JV Chakkalakal","year":"2005","unstructured":"Chakkalakal JV, Thompson J, Parks RJ, Jasmin BJ (2005) Molecular, cellular, and pharmacological therapies for Duchenne\/Becker muscular dystrophies. FASEB J 19(8):880\u2013891","journal-title":"FASEB J"},{"issue":"12","key":"11796_CR131","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies K (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4(12):1441\u20131444","journal-title":"Nat Med"},{"issue":"6607","key":"11796_CR132","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/384349a0","volume":"384","author":"JM Tinsley","year":"1996","unstructured":"Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384(6607):349\u2013353","journal-title":"Nature"},{"issue":"14","key":"11796_CR133","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.1021\/acs.jmedchem.0c00807","volume":"63","author":"A Babbs","year":"2020","unstructured":"Babbs A, Berg A, Chatzopoulou M, Davies KE, Davies SG, Edwards B, Elsey DJ, Emer E, Guiraud S, Harriman S et al (2020) 2-Arylbenzo[d]oxazole phosphinate esters as second-generation modulators of utrophin for the treatment of Duchenne muscular dystrophy. J Med Chem 63(14):7880\u20137891","journal-title":"J Med Chem"},{"key":"11796_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.116812","volume":"69","author":"M Chatzopoulou","year":"2022","unstructured":"Chatzopoulou M, Conole D, Emer E, Rowley JA, Willis NJ, Squire SE, Gill B, Brough S, Wilson FX, Wynne GM et al (2022) Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy. Bioorg Med Chem 69:116812","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"11796_CR135","doi-asserted-by":"publisher","first-page":"21492","DOI":"10.1038\/s41598-020-76338-1","volume":"10","author":"K Sengupta","year":"2020","unstructured":"Sengupta K, Loro E, Khurana TS (2020) PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD). Sci Rep 10(1):21492","journal-title":"Sci Rep"},{"issue":"21","key":"11796_CR136","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G et al (2020) Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94(21):e2270\u2013e2282","journal-title":"Neurology"},{"issue":"1","key":"11796_CR137","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A et al (2022) Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther 32(1):29\u201339","journal-title":"Nucleic Acid Ther"},{"issue":"18","key":"11796_CR138","doi-asserted-by":"publisher","first-page":"eabg4910","DOI":"10.1126\/sciadv.abg4910","volume":"7","author":"F Chemello","year":"2021","unstructured":"Chemello F, Chai AC, Li H, Rodriguez-Caycedo C, Sanchez-Ortiz E, Atmanli A, Mireault AA, Liu N, Bassel-Duby R, Olson EN (2021) Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv 7(18):eabg4910","journal-title":"Sci Adv"},{"issue":"1","key":"11796_CR139","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1038\/s41467-021-23996-y","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu L, Zhang C, Li H, Wang P, Gao Y, Mokadam NA, Ma J, Arnold WD, Han R (2021) Efficient precise in vivo base editing in adult dystrophic mice. Nat Commun 12(1):3719","journal-title":"Nat Commun"},{"issue":"3","key":"11796_CR140","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162809","volume":"133","author":"G Li","year":"2023","unstructured":"Li G, Jin M, Li Z, Xiao Q, Lin J, Yang D, Liu Y, Wang X, Xie L, Ying W et al (2023) Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy. J Clin Investig 133(3):e162809","journal-title":"J Clin Investig"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11796-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T13:07:43Z","timestamp":1689253663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11796-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":140,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["11796"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11796-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}